Link to this page
Experimental Conditions Ontology
Last uploaded:
December 16, 2024
Jump to:
| Preferred Name | ritonavir | |
| Synonyms |
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide |
|
| Definitions |
This is any condition in which the main influencing factor is ritonavir, a CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. Ritonavir is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Ritonavir is also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir for treatment of chronic hepatitis C virus genotype 1 infection and cirrhosis of the liver. |
|
| ID |
http://purl.obolibrary.org/obo/XCO_0001222 |
|
| created_by |
slaulederkind
|
|
| creation_date |
2024-01-08T15:19:08Z
|
|
| database_cross_reference |
CID:392622 MESH:D019438
|
|
| definition |
This is any condition in which the main influencing factor is ritonavir, a CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. Ritonavir is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Ritonavir is also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir for treatment of chronic hepatitis C virus genotype 1 infection and cirrhosis of the liver.
|
|
| has_exact_synonym |
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
|
|
| has_obo_namespace |
experimental_condition_ontology
|
|
| id |
XCO:0001222
|
|
| label |
ritonavir
|
|
| notation |
XCO:0001222
|
|
| prefLabel |
ritonavir
|
|
| treeView | ||
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping